The unmet need for COVID-19 treatment in immunocompromised patients.
BMC Infect Dis
; 22(1): 930, 2022 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2248900
ABSTRACT
BACKGROUND:
Immunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19. MAIN TEXT The recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclonal antibodies and the clinical benefit in high-risk COVID-19 patients. The study supports the use of early combination therapy in a subgroup of extremely high risk patients, and considers the combined strategy as a gold standard regimen to both increase the effectiveness of early treatment, especially in IC individuals, and, reduce the emergence of SARS-CoV-2 escape mutants.CONCLUSION:
A tailored and standardised therapeutic approach in case of IC out and inpatients with SARS-CoV-2 infection is needed.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
COVID-19
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
BMC Infect Dis
Asunto de la revista:
Enfermedades Transmisibles
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
S12879-022-07918-x
Similares
MEDLINE
...
LILACS
LIS